DCB控股(08040.HK)更名為"快意智能股份有限公司"
格隆匯9月1日丨DCB控股(08040.HK)公吿,於批准建議變更公司名稱的特別決議案於2022年8月1日舉行的股東特別大會上通過後,(i)開曼羣島公司註冊處處長已於2022年8月2日發出變更名稱註冊證書,確認公司英文名稱由"DCB Holdings Limited"更改為"Coolpoint Innonism Holding Limited",而公司現行的雙重外文的中文名稱由"DCB控股有限公司"更改為"快意智能股份有限公司";及(ii)香港公司註冊處處長已於2022年8月26日發出非香港公司變更名稱註冊證書,確認公司根據香港法例第622章《公司條例》第16部於香港註冊新的中英文名稱。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.